Clinical Trial Update: Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial is evaluating infusion of NY-ESO-1–specific TCR-engineered lymphocytes in patients with NY-ESO-1-expressing metastatic cancers;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Neuroblastoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Soft Tissue Sarcoma
• Synovial Sarcoma
• Triple-negative Breast Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• Anti-NY-ESO-1 TCR-gene engineered lymphocytes (TCR-T cells targeting NY-ESO-1)

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Sarcoma, Synovial, Sarcoma,Soft Tissue | Phase 1, Phase 2 | Status: RECRUITING